menu

NEWS

F Healthcare’s AI Technology Is First to Beat Radiologists in Stanford Chest X-ray Diagnostic Competition

CONCORD, Mass., Aug. 20, 2019 /PRNewswire/ — JF Healthcare, a medical diagnostic start-up based in Nanchang, China, is the first organization in the world to beat Stanford University radiologists in a competition designed by the Stanford Machine Learning group to compare the capability of artificial intelligence (AI) to human experts in interpreting chest x-rays. The AI team from JF Healthcare recently achieved an average AUC score (a measure of diagnostic accuracy) of 0.926 and is currently ranked No. 1 in the world on Stanford’s CheXpert leaderboard. Significantly, the JF team outperforms all three Stanford radiologists on the test set, demonstrating the...

READ MORE
CheXpert PR

Background In the United States, about half of all radiographic exams are X-rays, mostly of the chest. In other developing countries around the world, chest X-rays are even more widely used, for example, to detect lung cancer early, stop the spread of tuberculosis, and support the responsible use of antibiotics for pneumonia. Chest X-ray is the “bread and butter” for modern medical imaging to some extent. Because of the critical role of chest X-ray, on January 2019 the Machine Learning (ML) group at Stanford University lead by Dr. Andrew Ng released a large-scale chest X-ray dataset CheXpert for research, which...

READ MORE
CHINESE AI START-UP BEATS STANFORD TEAM IN X-RAY DIAGNOSTIC COMPETITION

The company’s goal is to make AI-driven x-ray analysis available across significant swathes of China’s rural areas. Jeff Rowe | Aug 23, 2019 11:52 am The Stanford Machine Learning group, based at Stanford University, recently launched a competition designed to compare AI’s capability in interpreting chest x-rays to the capabilities of human experts from Stanford.  And the humans lost. The winner was an AI team from JF Healthcare, a medical diagnostic start-up based in Nanchang, China, which outperformed all three Stanford radiologists involved with an average AUC score (a measure of diagnostic accuracy) of 0.926. According to a JF statement, the test demonstrates...

READ MORE
Ceres Nanosciences, University of Virginia, and George Mason University receive $600,000 award from the Virginia Catalyst to develop a Nanotrap® liquid biopsy collection device for cancer diagnostics

MANASSAS, Va. — June 4, 2019 — Ceres Nanosciences, Inc. (Ceres), University of Virginia (UVA), and George Mason University (Mason) today announced the receipt of a $600,000 award from the Virginia Catalyst for the development of a Nanotrap® liquid biopsy collection device. This award will be matched by $1.2 million in product development funding by Ceres Nanosciences. Cancer is the second leading cause of death world-wide and the global cancer burden is expected to grow to 23.6 million new cancer cases by 2030. Tissue biopsies are the current gold standard for detecting and obtaining information about cancer. By collecting cells from tumors, doctors can...

READ MORE
JÖRG DEBATIN TO CHAIR THE SUPERVISORY BOARD OF HUMMINGBIRD DIAGNOSTICS GMBH International healthcare leader strengthens miRNA experts

HEIDELBERG, BOSTON, October 9, 2018 – Hummingbird Diagnostics GmbH today announced that Prof. Dr. med. Jörg Debatin is appointed Chairman of the Supervisory Board with immediate effect. The former Vice President and Chief Technology Officer of GE Healthcare and CEO of Amedes AG directed the University Hospital Hamburg-Eppendorf for 8 years as its Medical Director and CEO. He started his professional career as a diagnostic radiologist at the University Hospitals of Duke, Stanford and Zürich (Switzerland). In 1999, he was appointed Professor of Diagnostic Radiology at the University of Essen. Debatin has studied medicine at the University of Heidelberg and holds...

READ MORE
Ceres Nanosciences’ Point-of-Care Nanotrap® Lyme Antigen Test System Granted Breakthrough Device Designation by U.S. Food and Drug Administration.

Manassas, VA – July 12, 2018 – Ceres Nanosciences (Ceres) announced today that is has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its new point-of-care Nanotrap® Lyme Antigen Test System. Under the Breakthrough Device program, formerly the Expedited Access Pathways program, the FDA works with a test developer to reduce the time and cost from development to approval. The Ceres’ Nanotrap® Lyme Antigen Test System is a powerful diagnostic test that is intended to be available in point-of-care settings, like a physician’s office or a walk-in clinic. Requiring only a patient’s urine sample, it will...

READ MORE
1 2 3 4
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER